Navigation Links
Par Pharmaceutical Receives Final Approval To Market Generic Starlix(R)
Date:9/10/2009

WOODCLIFF LAKE, N.J., Sept. 10 /PRNewswire-FirstCall/ -- Par Pharmaceutical Companies, Inc. (NYSE :PRX) today announced that it has received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application for nateglinide tablets. Nateglinide is a generic version of Novartis' Starlix(R). Annual U.S. sales of Starlix(R) are approximately $124 million, according to IMS Health data. Par will begin shipping the 60mg and 120mg strengths of nateglinide to the trade immediately.

Important information about nateglinide tablets

Nateglinide tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with Type II diabetes mellitus.

Nateglinide tablets are contraindicated in patients with a known hypersensitivity to the drug or its inactive ingredients, Type I diabetes and diabetic ketoacodosis.

About Par Pharmaceutical

Par Pharmaceutical, Inc. develops, manufactures and markets generic drugs and innovative branded pharmaceuticals for specialty markets. For press release and other company information, visit www.parpharm.com.

Safe Harbor Statement

Certain statements in this news release constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. To the extent any statements made in this news release contain information that is not historical, these statements are essentially forward-looking and, as such, are subject to known and unknown risks, uncertainties and contingencies, many of which are beyond the control of the Company, which could cause actual results and outcomes to differ materially from those expressed herein. Risk factors that might affect such forward-looking statements include those set forth in Item 1A of the Company's Annual Report on Form 10-K for the year ended December 31, 2008, in Item 1A of the Company's subsequent Quarterly Reports on Form 10-Q, in other of the Company's filings with the SEC from time to time, including Current Reports on Form 8-K, and on general industry and economic conditions. Any forward-looking statements included in this news release are made as of the date hereof only, based on information available to the Company as of the date hereof, and, subject to any applicable law to the contrary, the Company assumes no obligation to update any forward-looking statements.


'/>"/>
SOURCE Par Pharmaceutical Companies, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Reportlinker Adds US and European Radiopharmaceuticals Market Report
2. Tianyin Pharmaceutical Co., Inc. Has Four Products Included in Chinas Essential Drug List
3. KV Pharmaceutical Sets Record Date for Stockholder Action by Written Consent
4. Cumberland Pharmaceuticals Launches Caldolor(R) in the United States for Treatment of Pain and Fever
5. Isis Pharmaceuticals to Present at Morgan Stanleys Global Healthcare Unplugged Conference
6. FDA pharmaceutical import alert
7. KV Pharmaceutical Appoints Interim Chief Financial Officer
8. Rib-X Pharmaceuticals, Inc. Appoints Tom Kassberg Chief Business Officer
9. Jazz Pharmaceuticals to Present at Two Upcoming Investor Conferences
10. Anadys Pharmaceuticals to Present at Two Upcoming Investor Conferences
11. Amira Pharmaceuticals to Present at Thomas Weisel Partners Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/21/2017)... Doylestown, Pa. (PRWEB) , ... ... ... leading provider of technology-enabled clinical trial solutions, today announced the further expansion ... types of applications they can leverage as part of Bioclinica’s extensive and ...
(Date:2/21/2017)... ... February 21, 2017 , ... A February 6 article ... weight loss. It found that the treatments have led to significant improvements in weight ... to unassisted efforts. It also noted very few problematic results relating to the treatment. ...
(Date:2/20/2017)... ... February 21, 2017 , ... Nancy Johnston Toll marks her debut ... Getting Over the Bump in the Road ” (published by Xlibris). Inspired from her ... cope with the ups and downs experienced by anyone going through cancer treatment and ...
(Date:2/20/2017)... ... February 20, 2017 , ... Researchers at the University of ... well as a marker that may predict response to a particular class of drugs, ... of cancer as well. The new findings were published in Proceedings of the National ...
(Date:2/20/2017)... ... 2017 , ... Best Doctors® and IBM today announced that ... that want to help members of their workforce battling cancer. Through the Best ... suite of oncology offerings for insights on cancer treatment options, ranging from standard ...
Breaking Medicine News(10 mins):
(Date:2/21/2017)... Lexmark International, ... solution that connects Lexmark multifunction printers (MFPs) to EDCO ... leading scanning and indexing software solutions for medical records. ... use a Lexmark MFP at the point of care ... facilities reach HIMSS Stage 7 through state-of-the-art ...
(Date:2/21/2017)... IDAHO FALLS, Idaho , Feb. 21, 2017 /PRNewswire/ ... is has completed a private placement with certain investors ... preferred stock of the Company, Series C Convertible Redeemable ... Stock accrues dividends at an annual rate of 6% ... share.  The Company plans to use the proceeds for ...
(Date:2/21/2017)... SAN JOSE, Calif. , Feb. 21, 2017 ... announced that its Cadence ® Tensilica ® Fusion ... HaLow ™ MAC IP offering. The licensable IP targets ... smart city and industrial applications. M2B leveraged the Fusion F1 ... to run value-added applications like voice trigger, audio identification and ...
Breaking Medicine Technology: